Inhibition of Human Epidermal Growth Factor Receptor-2 (HER-2) from Pomelo (Citrus maxima) Flavonoid Compounds: an In Silico Approach

Roihatul Mutiah, Tanaya Jati Dharma Dewi, Arief Suryadinata, Kesimira Qonita


Citrus maxima or pomelo is a plant that has potential as an anticancer because it contains flavonoids. One of the targets of breast anticancer receptors is the HER-2 protein. This research aims to determine the anticancer activity, the toxicity of the compound, and the prediction of physicochemical properties of flavonoids contained in Citrus maxima through in silico approach. Flavonoid compounds were screened using SwissADME with Lipinski's rule of five, Torsion, TPSA, and P-Gp Non-Substrate. Compounds that passed the screening were carried out molecular docking to the HER-2 receptor (PDB ID: 3PP0) using the Molegro Virtual Docker (MVD). The HER-2 receptor (GDP ID: 3PP0) was declared valid because it had RMSD<2Å. The results showed that there were 11 flavonoid compounds that passed the screening and had a lower rerank score than the comparison compound Trastuzumab. Toxicity was predicted using the Protox II online tool and the results showed that the flavonoid compounds were in the safe limits, namely classes 5 and 3. Based on this research, it can be concluded that acacetin, diosmetin, honyucitrin, isosinensetin, nobiletin, sinensetin, and tangeretin can be candidates for breast cancer drugs based on natural ingredients.

Keywords: breast cancer, Citrus maxima, HER-2, in silico.

Full Text:



Chagas, C.M., Moss, S., and Alisaraie, L., 2018, Drug Metabolites and Their Effects on the Development of Adverse Reactions: Revisiting Lipinski’s Rule of Five, International Journal of Pharmaceutics, 549(1–2), 133–149. CrossRef

El-Din, H.M.A., Loutfy, S.A., Fathy, N., Elberry, M.H., Mayla, A.M., Kassem, S., and Naqvi, A., 2016, Molecular Docking Based Screening of Compounds against VP40 from Ebola Virus, Bioinformation, 12(3), 192–196. CrossRef

Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., et al., 2018, Breast Cancer Development And Progression: Risk Factors, Cancer Stem Cells, Signaling Pathways, Genomics, and Molecular Pathogenesis, Genes & diseases, 5(2), 77-106. CrossRef

Finch, A., and Pillans, P., 2014, P-Glycoprotein and Its Role in Drug-Drug Interactions, Australian Prescriber, 37(4), 137–39. CrossRef

Ha, C.H.H., Fatima, A., and Gaurav, A., 2015, In Silico Investigation of Flavonoids as Potential Trypanosomal Nucleoside Hydrolase Inhibitors, Advances in Bioinformatics, 2015, 826047. CrossRef

Holla, S.N., Nayak, V., Bairy, K.L., Tripathy, A., and Holla, S., 2016, Her-2 Gene, Receptors and Drug Target: A Systematic Review, International Journal of Pharmacy and Pharmaceutical Sciences, 8(4), 4–9. Link

Huszno, J., Les, D., Sarzyczny-Slota, D., and Nowara, E., 2013, Cardiac Side Effects of Trastuzumab in Breast Cancer Patients-Single Centere Experiences, Contemp Oncol (Pozn), 17(2), 190–195. CrossRef

Jain, A.N., and Nicholls, A., 2008, Recommendations for Evaluation of Computational Methods, Journal of Computer-Aided Molecular Design, 22(3–4), 133–139. CrossRef

Jiang, N., Lin, J-J., Wang, J., Zhang, B-N., Li, A., Chen, Z-Y., et al., 2018, Novel Treatment Strategies for Patients with HER2 Positive Breast Cancer Who Do Not Benefit from Current Targeted Therapy Drugs, Experimental and Therapeutic Medicine, 16(3), 2183–2192. CrossRef

Kartasasmita, R.E., Anugrah, R., and Tjahjono, D.H., 2015, Kajian Docking Dan Prediksi Beberapa Aspek Farmakokinetika Desain Molekul Turunan Kuinin Sebagai Upaya Menemukan Kandidat Senyawa Antimalaria Yang Baru, Kartika Jurnal Ilmiah Farmasi, 3(1), 6–13. CrossRef

Kementerian Kesehatan Republik Indonesia, 2015, Buletin Kanker. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI.

Kesuma, D., Siswandono, S., Purwanto, B.T., and Hardjono, S., 2018, Uji in Silico Aktivitas Sitotoksik dan Toksisitas Senyawa Turunan N-(Benzoil)-N’- Feniltiourea Sebagai Calon Obat Antikanker, Journal of Pharmaceutical Science and Clinical Research, 3(1), 1-11. CrossRef

Liao, N., 2016, HER2-Positive Breast Cancer, How Far Away from the Cure?-On the Current Situation of Anti-HER2 Therapy in Breast Cancer Treatment and Survival of Patients, Chinese Clinical Oncology, 5(3), 41. CrossRef

Puspita, D., 2020, Studi In Silico Senyawa dalam Ekstrak Etanol 96% Daun Krisan (Chrysanthemum cinerariifolium (Trev.)) terhadap Reseptor Estrogen Alfa (5W9C) [Skripsi], Malang: Program Studi Farmasi UIN Maulana Malik Ibrahim Malang.

Susanti, N.M.P., Saputra, D.P.D., Hendrayati, P.L., Parahyangan, I.P.D.N., and Swandari, I.A.D.G., 2018, Molecular Docking Sianidin Dan Peonidin Sebagai Antiinflamasi Pada Aterosklerosis Secara In Silico, Jurnal Farmasi Udayana, 7(1), 28-33. CrossRef

Saxena, A.R., Ilic, Z., Sripada, V., and Crawford, D.R., 2020, Lower Concentrations of Curcumin Inhibit Her2-Akt Pathway Components In Human Breast Cancer Cells, and Other Dietary Botanicals Potentiate This and Lapatinib Inhibition, Nutrition Research, 79, 93-104. CrossRef

Shivananda, A., Muralidhara R.A.O.D., and Jayaveera K.N., 2013, Anticancer Activity of Extracts of Various Fractions of Citrus maxima (J. Burm.) Merr. on HeLa Cell Line, Journal of Pharmacy and Chemistry, 7(1), 3–7.

Silverman, R.B., and Holladay, M.W., 2014, The Organic Chemistry of Drug Design and Drug Action, Third Edition, 123-163, Academic Press.

Sulastri, H., and Murti, K., 2017, Hubungan Antara Overekspresi Vascular Endothelial Growth Factor Dengan ER, PR, HER-2, Ki67 Pada Subtipe Molekular Karsinoma Payudara Invasif Tidak Spesifik, Jurnal Kedokteran dan Kesehatan, 4(1), 25–34.

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: A Cancer Journal for Clinicians, 71(3), 209-249. CrossRef

Thavanapong, N., 2006, The Essential Oil From Peel and Flower of Citrus maxima. [Tesis]. Master of Pharmasy, Silpakorn University.

Vu, T., and Claret, F.X., 2012, Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer, Frontiers in Oncology, 2, 62. CrossRef

World Health Organization. 2018. Cancer. (accessed: 28 Februari 2021).

Yeh, E.T.H., Tong, A.T., Lenihan, D.J., Yusuf, S.W., Swafford, J., Champion, C., et al., 2004, Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management, Circulation, 109(25), 3122–3131. CrossRef

Yersal, O., and Barutca, S., 2014, Biological Subtypes of Breast Cancer: Prognostic and Therapeutic Implications, World Journal of Clinical Oncology, 5(3), 412–424. CrossRef


Copyright (c) 2022 Kesimira Qonita

Indexed by:




Indonesian Society for Cancer Chemoprevention